white-paper

Developing and Demonstrating Bioequivalence of Semi-Solid Dosage Forms

The US Food and Drug Administration (FDA) issued new draft guidance in December 2016 indicating that generic manufacturers can demonstrate bioequivalence for a specific semi-solid dosage form using predictive in vitro testing as a surrogate for in vivo testing.

Thank you for registering!

You now have the option of downloading the resource or viewing the web version below.